Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 1/20 | 0.47 |
| ▸ | PRKACA | P17612 | 1/20 | 0.41 |
| ▸ | PRKACG | P22612 | 1/20 | 0.41 |
| ▸ | PRKACB | P22694 | 1/20 | 0.41 |
| ▸ | HTR3A | P46098 | 1/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.37 |
| ▸ | PRCP | P42785 | 1/20 | 0.37 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.36 |
| ▸ | CTSK | P43235 | 1/20 | 0.35 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.35 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22589151 | 1.00 | CHRNA7 (0.47) | CHRNA7PRKACAPRKACGPRKACBHTR3A | |
| Hydrochloric Acid SCHEMBL17514204 | 0.98 | CHRNA7 (0.46) | CHRNA7PRKACAPRKACGPRKACBHTR3A | |
| SCHEMBL18387 | 0.81 | CSNK1D (0.43) | PRKACAPRKACGPRKACBPRCPCTSK | |
| SCHEMBL21717791 | 0.81 | MAPT (0.44) | PRKACAPRKACGPRKACBCTSKTAAR1 | |
| SCHEMBL14839620 | 0.81 | PRKACA (0.41) | PRKACAPRKACGPRKACBCTSK | |
| SCHEMBL5545595 | 0.81 | MAPT (0.44) | CHRNA7PRKACAPRKACGPRKACBSLC6A2 | |
| SCHEMBL8321907 | 0.81 | CSNK1D (0.43) | PRKACAPRKACGPRKACBPRCPCTSK | |
| SCHEMBL280628 | 0.81 | CSNK1D (0.43) | PRKACAPRKACGPRKACBPRCPCTSK | |
| SCHEMBL3399522 | 0.81 | PRKACA (0.47) | CHRNA7PRKACAPRKACGPRKACBSLC6A2 | |
| SCHEMBL14683840 | 0.81 | PRKACA (0.41) | CHRNA7PRKACAPRKACGPRKACBSLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4732837-A2 | NOVEL PRMT5 INHIBITORS | Amgen Inc. (US) | 2026-04-29 | — | — | EP | disclosed |
| EP-4263545-B1 | PRMT5 INHIBITORS | AMGEN INC (US) | 2026-04-01 | — | — | EP | disclosed |
| US-12497395-B2 | Small molecule bromodomain inhibitors and uses therof | CONVERGENE, LLC | 2025-12-16 | — | — | US | disclosed |
| EP-4424379-A2 | SMALL MOLECULE BROMODOMAIN INHIBITORS AND USES THEREOF | CONVERGENE LLC (US) | 2024-09-04 | — | — | EP | disclosed |
| EP-3958867-B1 | SMALL MOLECULE BROMODOMAIN INHIBITORS AND USES THEREOF | CONVERGENE LLC (US) | 2024-06-26 | — | — | EP | disclosed |
| US-20240092794-A1 | NOVEL PRMT5 INHIBITORS | AMGEN INC. (US) | 2024-03-21 | — | — | US | disclosed |
| US-11845760-B2 | PRMT5 inhibitors | AMGEN INC. (US) | 2023-12-19 | — | — | US | disclosed |
| US-20220259200-A1 | SMALL MOLECULE BROMODOMAIN INHIBITORS AND USES THEROF | CONVERGENE, LLC | 2022-08-18 | — | — | US | disclosed |
| US-20220194955-A1 | NOVEL PRMT5 INHIBITORS | AMGEN INC. (US) | 2022-06-23 | — | — | US | disclosed |
| WO-2022132914-A1 | PRMTS INHIBITORS | AMGEN INC. (US) | 2022-06-23 | — | — | WO | disclosed |
| EP-1856058-A2 | PHTHALAZINE, AZA- AND DIAZA-PHTHALAZINE COMPOUNDS AND METHODS OF USE | Amgen Inc. (US) | 2007-11-21 | — | — | EP | disclosed |
| US-7262212-B2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-28 | — | — | US | disclosed |
| WO-2006094187-A2 | PHTHALAZINE, AZA- AND DIAZA-PHTHALAZINE COMPOUNDS AND METHODS OF USE | AMGEN INC (US) | 2006-09-08 | — | — | WO | disclosed |
| US-20060199817-A1 | Phthalazine, aza- and diaza-phthalazine compounds and methods of use | AMGEN INC. (US) | 2006-09-07 | — | — | US | disclosed |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-04 | — | — | US | disclosed |
| EP-1555267-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-07-20 | — | — | EP | disclosed |
| CN-1022685-C | Hydrofluorene derivatives | OTSUKA PHARMA CO LTD (JP) | 1993-11-10 | — | — | CN | disclosed |
| US-5017724-A | Antihypoxic, CNS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1991-05-21 | — | — | US | disclosed |
| EP-0267024-B1 | HYDROFLUORENE DERIVATIVES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1991-05-02 | — | — | EP | disclosed |
| EP-0267024-A2 | Hydrofluorene derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1988-05-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060199817-A1 | Phthalazine, aza- and diaza-phthalazine compounds and methods of use | DAPK2, CDK2, DAPK1 | CHRNA7 2913/4885PRKACA 10/4885PRKACG 30/4885 |
| US-20240092794-A1 | NOVEL PRMT5 INHIBITORS | PRMT5, PRMT1, PRMT6 | CHRNA7 4255/4885PRKACA 1272/4885PRKACG 1061/4885 |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | NR2C2, NR4A3, NR4A2 | CHRNA7 997/4885PRKACA 4566/4885PRKACG 4617/4885 |
| US-12497395-B2 | Small molecule bromodomain inhibitors and uses therof | BRD4, BRPF3, BICRA | CHRNA7 4089/4885PRKACA 3819/4885PRKACG 3848/4885 |
| US-20220259200-A1 | SMALL MOLECULE BROMODOMAIN INHIBITORS AND USES THEROF | BRPF3, BRDT, BRD3 | CHRNA7 3549/4885PRKACA 2623/4885PRKACG 2766/4885 |
| US-11845760-B2 | PRMT5 inhibitors | PRMT5, PRMT1, PRMT6 | CHRNA7 4312/4885PRKACA 1100/4885PRKACG 937/4885 |
| US-20220194955-A1 | NOVEL PRMT5 INHIBITORS | PRMT5, PRMT1, PRMT6 | CHRNA7 4255/4885PRKACA 1272/4885PRKACG 1061/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.